Skip to content

Blog

Category: BioAgilytix Insight

New Research on the Diagnostic Journey of Patients with Ankylosing Spondylitis

BioAgilytix's Regan Reynolds shares how her own diagnostic journey with Ankylosing Spondylitis (AS) inspired her to participate in a non-interventional research project on how AS…

Read More

Women in STEM: Discussing Technology with BioAgilytix’s Whitney Gonzales this #WomensHistoryMonth

Today we continue our celebration of Women’s History Month by highlighting another BioAgilytix team member – this time from the technology side of our business.…

Read More

Answers to Your Questions on Immunogenicity Testing for Biosimilars: Part 2

BioAgilytix’s Todd Lester answers additional questions submitted by attendees of his recent Bioanalysis Zone webinar on immunogenicity testing for biosimilars.

Read More

Questions on Immunogenicity Testing for Biosimilars Answered: Part 1

BioAgilytix’s Todd Lester answers questions submitted by attendees of his recent Bioanalysis Zone webinar on immunogenicity testing for biosimilars.

Read More

Bioanalytical Testing Under GMP: Assuring Biologic Safety & Efficacy via Impurities Assays

We discuss the need to put phase-appropriate methods in place to identify and quantify both process- and host-cell related impurities throughout the drug development process.

Read More

Bioanalytical Strategies to Support Biosimilar Programs: How BioAgilytix is Helping to Shape Best Practices

BioAgilytix has been fortunate enough to have several of our team members participate as co-authors on all three AAPS white papers in the series on…

Read More

A Dose of Pharma and Biotech News: December 12, 2019

With innovative research driving pharmaceutical and biotech breakthroughs, industry progress is accelerating at a rapid pace. We've compiled some recent industry articles on the latest…

Read More

BioAgilytix Team Q&A: Meet Tatjana Ackermann, Quality Assurance Auditor

We strive to foster an environment where our team members can continually grow within their role and within the company – not only upwards, but…

Read More

CRISPR-Cas9 Milestones: The First In Vivo Clinical Trial Is Now Underway in Boston

The first in-human in vivo clinical trial using CRISPR-Cas9 is now open for enrollment; we take a closer look at this genome editing technology to…

Read More

BioAgilytix Team Q&A: Meet Janett Schwarz, Principal Investigator at BioAgilytix

In our latest Team Q&A, we talk to Janett Schwarz, Principal Investigator at BioAgilytix’s European headquarters, about how her role has evolved since joining our…

Read More